soul trial oral semaglutide cardiovascular outcomes results 2025 2024 nejm 💥Soul study group recently shared semaglutide cardiovascular outcomes news today

Diabetes, Obesity, and Metabolism, 25 (4), 975-984

The type III ANOVA analysis via Satterthwaites degrees of freedom was performed using the R package lmerTest [47] to assess the significance of the main effects, whereas significant relationships were further explored via estimated marginal means analysis using the package emmeans V1.11.1 [48], thus, a Tukey-adjusted contrasts pair wise comparison was also carried out

Percent Daily Values are based on a 2,000 calorie diet

Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide